BEONE MEDICINES LTD (ONC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$358.26-1.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
BeOne Medicines grows revenue about 20% yearly, reaching $6.4B in 2026. Profit margins stay high near 80%. Operating income rises toward $750-$850M. New cancer treatments in late-stage trials boost future growth.
Growth could slow if new drugs fail late trials. Profit margins may shrink if costs rise. Competition could limit market share gains.
The price is about 7% above our fair value near $285. Analysts expect 19% revenue growth, which aligns with our view. Our fair value is below the Street median, reflecting cautious optimism.
Breaks if: gross margin falls below 75% in FY26
Breaks if: operating income falls below $700M in FY26
Breaks if: failure to advance key programs to Phase 3 by mid-2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on expanding its market presence and improving margins. The current thesis state is intact, driven by recent earnings beats and a solid growth trajectory for its key product, BRUKINSA.
The valuation is considered expensive compared to peers, reflecting high expectations for continued growth. The market seems to be pricing in a strong performance, with a noted expectations gap indicating that some positive surprises may already be anticipated.
Fundamentals are likely to continue improving, as management is on track to meet its goals for revenue growth and operating income. However, there is a moderate risk of missing expectations due to the erratic nature of earnings surprises in the industry.
The thesis hinges on maintaining momentum in the healthcare sector, particularly if leading companies continue to report strong earnings. Additionally, any negative shifts in guidance or economic indicators, such as a weakening jobs report, could impact ONC's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company secured a pharmaceutical-tariff exemption. This supports global market expansion for BRUKINSA. FDA approval marks a turning point for ONC. It advances sonrotoclax clinical and regulatory milestones. Recent financial performance remains strong, with revenue surging 30%.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $6.3B in FY26
Continue to grow BRUKINSA sales globally, including U.S., Europe, and other key markets, driving strong revenue growth.
Stated as a priority in 2 of last 2 quarters. BRUKINSA global revenues increased from $1.1 billion in 2026-Q1 to $1.2 billion in 2026-Q2, representing 31% year-over-year growth in Q2. Management consistently emphasizes BRUKINSA's leadership and global expansion, and the revenue trajectory is delivering on this growth priority.
“BRUKINSA global revenues of $1.2 billion for Q2, up 31% year-over-year.”
“BRUKINSA global revenues of $1.1 billion for Q1, up 38% year-over-year.”
Overall, ONC's outlook remains positive for the next 1 to 3 years, driven by strong management execution and sector support. Not investment advice.